

IN THE CLAIMS:

---

1. (Currently Amended) A method for suppressing disease caused or enhanced by effects of intracellular iron mismanagement comprising:

increasing the intracellular amount of at least one ferritin-H or a derivative thereof to an effective level wherein exogenous ferritin-H or derivative thereof is introduced into globin-producing cells.

2. (Cancel)

3. (Original) The method for suppressing disease of Claim 1 wherein the globin-producing cells are fused with liposomal constructs containing ferritin-H or derivative thereof.

Claims 4 through 10 (Previously Canceled)

11. (Original) A method for treating sickle cell disease comprising:  
suppressing the expression of adult  $\beta$ -globin genes in globin-producing cells with  
ferritin-H or a derivative thereof.

12. (Original) The method for treating sickle cell disease of Claim 11 wherein exogenous ferritin-H or a derivative thereof is introduced into globin-producing cells.

13. (Original) The method for treating sickle cell disease of Claim 12 wherein the globin-producing cells are fused with liposomal constructs containing ferritin-H or a derivative thereof.

Claims 14 through 18 (Previously Canceled)

19. (Original) The method for treating sickle cell disease of claim 11 wherein the ferritin-H or derivative thereof binds to the promoter region of the  $\beta$ -globin gene.

31  
Claims 20 and 21 (Canceled)

22. (Currently Amended) A pharmaceutical composition comprising  
ferritin-H or a derivative thereof; and,  
a cell specific targeting ligand for introduction into globin producing cells.

23. (Previously Canceled)

---